We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
-2.24%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.69B
AUM Growth
+$368M
Cap. Flow
+$592M
Cap. Flow %
35.11%
Top 10 Hldgs %
42.19%
Holding
93
New
24
Increased
33
Reduced
11
Closed
20

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$82.5M
2
APLT
Applied Therapeutics
APLT
+$64.9M
3
NUVL
Nuvalent
NUVL
+$56M
4
VERA icon
Vera Therapeutics
VERA
+$47.6M
5
CYTK icon
Cytokinetics
CYTK
+$44.1M

Top Sells

Rank Stock Value
1
NARI
Inari Medical, Inc. Common Stock
NARI
+$63.9M
2
INSM icon
Insmed
INSM
+$50.4M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$33.8M
4
JANX icon
Janux Therapeutics
JANX
+$22M
5
EW icon
Edwards Lifesciences
EW
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARDX icon
76
Ardelyx
ARDX
$997M
– –
-500,000
Closed -$3.44M
AVDL
77
PUT
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-2,000,000
Closed -$26.2M
BDX icon
78
Becton Dickinson
BDX
$48.2B
– –
-30,000
Closed -$7.23M
BHVN icon
79
CALL
Biohaven
BHVN
$2.21B
– –
-500,000
Closed -$25M
BMY icon
80
Bristol-Myers Squibb
BMY
$132B
– –
-250,000
Closed -$12.9M
BRKR icon
81
Bruker
BRKR
$8.14B
– –
-125,000
Closed -$8.63M
CRNX icon
82
Crinetics Pharmaceuticals
CRNX
$8.92B
– –
-205,000
Closed -$10.5M
EW icon
83
Edwards Lifesciences
EW
$51.7B
– –
-275,000
Closed -$18.1M
GILD icon
84
Gilead Sciences
GILD
$165B
– –
-200,000
Closed -$16.8M
JANX icon
85
Janux Therapeutics
JANX
$967M
– –
-485,000
Closed -$22M
PEN icon
86
Penumbra
PEN
$12.8B
– –
-15,000
Closed -$2.91M
PRME icon
87
Prime Medicine
PRME
$559M
– –
-1,070,000
Closed -$4.14M
PTCT icon
88
PTC Therapeutics
PTCT
$6.12B
– –
-80,000
Closed -$2.97M
RLMD icon
89
Relmada Therapeutics
RLMD
$527M
– –
-490,000
Closed -$1.59M
TARS icon
90
Tarsus Pharmaceuticals
TARS
$2.84B
– –
-230,000
Closed -$7.56M
ZVRA icon
91
Zevra Therapeutics
ZVRA
$686M
– –
-525,000
Closed -$3.64M
ITCI
92
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-30,000
Closed -$2.2M
NARI
93
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-1,550,000
Closed -$63.9M
1 2 3
4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $3.52B AUM 52.63% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Vestal Point Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Vestal Point Capital held 93 positions worth $1.69B, up 28% from $1.32B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Vestal Point Capital deployed $592M of net new capital in Q4 2024, opening 24 new positions and adding to 33 existing holdings. Its largest new stake was Merck: 800,000 shares worth $79.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $50.4M trimmed.

  • Vestal Point Capital's largest Q4 2024 buy was Merck: 800,000 shares worth $79.6M.
  • Vestal Point Capital added most to Applied Therapeutics in Q4 2024, an estimated $64.9M increase.
  • Vestal Point Capital's biggest Q4 2024 reduction was Insmed, cutting an estimated $50.4M.
  • Vestal Point Capital fully exited Inari Medical, Inc. Common Stock in Q4 2024, selling an estimated $63.9M.
  • Vestal Point Capital's ten largest holdings make up 42% of its $1.69B portfolio in Q4 2024.
  • Vestal Point Capital opened 24 new positions and closed 20 in Q4 2024.
  • Vestal Point Capital's portfolio value rose 28% quarter-over-quarter to $1.69B.

Based on Vestal Point Capital's 13F filing for Q4 2024, filed 14 Feb 2025.